What does PHARMA-LOUVE do?

PHARMA-LOUVE is a pharmacy in Seneffe. Private Limited, started on 13 December 2007, 1 establishment.

What is the address of PHARMA-LOUVE?

The registered office of PHARMA-LOUVE is located at Rue des Canadiens 24, 7180 Seneffe.

Is PHARMA-LOUVE still active?

Yes. According to the CBE (30 October 2026) PHARMA-LOUVE is active, legal situation “Normale toestand”, started on 13 December 2007.

Is PHARMA-LOUVE registered on Peppol?

Yes, PHARMA-LOUVE is registered on the Peppol network with ID 0208:0894160549.

What is the enterprise number of PHARMA-LOUVE?

The enterprise number of PHARMA-LOUVE is BE0894160549.

When was PHARMA-LOUVE founded?

PHARMA-LOUVE was founded on 13 December 2007.

Who are the directors of PHARMA-LOUVE?

According to the 2025 annual accounts, the directors of PHARMA-LOUVE are: DEVANTHINIC PHARMA.

Is PHARMA-LOUVE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 December 2007; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMA-LOUVE make in 2025?

PHARMA-LOUVE posted a profit after taxes of € 110,741 in financial year 2025.

What is the revenue of PHARMA-LOUVE?

As a small company, PHARMA-LOUVE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 395,901.

How much does an employee at PHARMA-LOUVE earn?

The average wage cost per full-time employee at PHARMA-LOUVE was € 76,400 in 2025: staff costs of € 198,583 for 2.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA-LOUVE have?

According to the 2025 annual accounts, PHARMA-LOUVE has 2.6 full-time equivalents (FTE).

PHARMA-LOUVE (Private Limited) - Seneffe - BE0894160549

Dossier PHARMA-LOUVE, printed on 30 October 2026 from databakkes.be/en/0894160549/pharma-louve. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Figures corrected NBB

Corrected annual account filed for 2024.
Busy address KBO

11 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

PHARMA-LOUVE from Seneffe, company number BE0894160549, closed financial year 2025 with a result of € 110,741 after tax. For that financial year PHARMA-LOUVE recorded a gross margin of € 395,901 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € 115,268 to € 110,741. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.

What it is worth Growing

€ 1.1 million

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 110,741

▼ 4% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 648,938

▲ 47% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 700,095.

People and assets in 2025

Full-time equivalents

2.6

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 198,583

▲ 9% vs 2024

€ 76,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 941

▼ 74% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 266,848

▼ 11% vs 2024

€ 31,968 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 182,196

▲ 34% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 24,231

▲ 12% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 357,463 Gross margin 2022: € 357,463 First fiscal year in the series	€ 345,345 Gross margin 2023: € 345,345 ▼ 3% vs 2022 (€ 357,463) Unfavourable step	€ 410,913 Gross margin 2024: € 410,913 ▲ 19% vs 2023 (€ 345,345) Favourable step	€ 395,901 Gross margin 2025: € 395,901 ▼ 4% vs 2024 (€ 410,913) Unfavourable step	▼ 4%
Profit after taxes	€ 88,560 Profit after taxes 2022: € 88,560 First fiscal year in the series	€ 67,756 Profit after taxes 2023: € 67,756 ▼ 23% vs 2022 (€ 88,560) Unfavourable step	€ 115,268 Profit after taxes 2024: € 115,268 ▲ 70% vs 2023 (€ 67,756) Favourable step	€ 110,741 Profit after taxes 2025: € 110,741 ▼ 4% vs 2024 (€ 115,268) Unfavourable step	▼ 4%
Equity	€ 781,330 Equity 2022: € 781,330 First fiscal year in the series	€ 849,086 Equity 2023: € 849,086 ▲ 9% vs 2022 (€ 781,330) Favourable step	€ 964,354 Equity 2024: € 964,354 ▲ 14% vs 2023 (€ 849,086) Favourable step	€ 1,075,095 Equity 2025: € 1,075,095 ▲ 11% vs 2024 (€ 964,354) Favourable step	▲ 11%
Total debts	€ 522,490 Total debts 2022: € 522,490 First fiscal year in the series	€ 524,108 Total debts 2023: € 524,108 Unchanged (€ 522,490) Unfavourable step	€ 458,100 Total debts 2024: € 458,100 ▼ 13% vs 2023 (€ 524,108) Favourable step	€ 474,850 Total debts 2025: € 474,850 ▲ 4% vs 2024 (€ 458,100) Unfavourable step	▲ 4%
Cash	€ 241,984 Cash 2022: € 241,984 First fiscal year in the series	€ 307,065 Cash 2023: € 307,065 ▲ 27% vs 2022 (€ 241,984) Favourable step	€ 442,379 Cash 2024: € 442,379 ▲ 44% vs 2023 (€ 307,065) Favourable step	€ 648,938 Cash 2025: € 648,938 ▲ 47% vs 2024 (€ 442,379) Favourable step	▲ 47%
Land & buildings	€ 319,964 Land & buildings 2022: € 319,964 First fiscal year in the series	€ 305,112 Land & buildings 2023: € 305,112 ▼ 5% vs 2022 (€ 319,964) Unchanged	€ 290,259 Land & buildings 2024: € 290,259 ▼ 5% vs 2023 (€ 305,112) Unchanged	€ 275,406 Land & buildings 2025: € 275,406 ▼ 5% vs 2024 (€ 290,259) Unchanged	▼ 5%
Retained profit	€ 406,330 Retained profit 2022: € 406,330 First fiscal year in the series	€ 474,086 Retained profit 2023: € 474,086 ▲ 17% vs 2022 (€ 406,330) Favourable step	€ 589,354 Retained profit 2024: € 589,354 ▲ 24% vs 2023 (€ 474,086) Favourable step	€ 700,095 Retained profit 2025: € 700,095 ▲ 19% vs 2024 (€ 589,354) Favourable step	▲ 19%
Bank debt	€ 371,176 Bank debt 2022: € 371,176 First fiscal year in the series	€ 328,957 Bank debt 2023: € 328,957 ▼ 11% vs 2022 (€ 371,176) Favourable step	€ 298,209 Bank debt 2024: € 298,209 ▼ 9% vs 2023 (€ 328,957) Favourable step	€ 266,848 Bank debt 2025: € 266,848 ▼ 11% vs 2024 (€ 298,209) Favourable step	▼ 11%
Balance sheet total	€ 1,303,820 Balance sheet total 2022: € 1,303,820 First fiscal year in the series	€ 1,373,194 Balance sheet total 2023: € 1,373,194 ▲ 5% vs 2022 (€ 1,303,820) Unchanged	€ 1,422,454 Balance sheet total 2024: € 1,422,454 ▲ 4% vs 2023 (€ 1,373,194) Unchanged	€ 1,549,945 Balance sheet total 2025: € 1,549,945 ▲ 9% vs 2024 (€ 1,422,454) Unchanged	▲ 9%
Employees (FTE)	2.6 Employees (FTE) 2022: 2.6 First fiscal year in the series	2.7 Employees (FTE) 2023: 2.7 ▲ 0.1 vs 2022 (2.6) Unchanged	2.6 Employees (FTE) 2024: 2.6 ▼ 0.1 vs 2023 (2.7) Unchanged	2.6 Employees (FTE) 2025: 2.6 Unchanged (2.6) Unchanged

Key figures of PHARMA-LOUVE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA-LOUVE?

What happened at PHARMA-LOUVE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 24, 2026 New annual accounts for financial year 2025: profit of € 110,741 (▼ 4% vs 2024). filed late Source: NBB ↗
2014 DEVANTHINIC PHARMA became a director. NBB
Dec 13, 2007 Start of the company according to the CBE. KBO
Dec 10, 2007 New establishment in La Louvière. KBO

In short

From € 88,560 profit in 2022 to € 110,741 profit in 2025.

Paid € 128,778 in corporate taxes since 2022.

Best year ever: 2024, with € 115,268 profit.

On average € 152,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

DEVANTHINIC PHARMA 100%

The stake of DEVANTHINIC PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA-LOUVE

Behind PHARMA-LOUVE is DEVANTHINIC PHARMA. The shares are held by DEVANTHINIC PHARMA (100%).

Directors

According to the 2025 annual accounts

DEVANTHINIC PHARMA

Director · represented by Anne André

Also active at: PHARMACIE DE LA DRÊVE, PHARMACIE DE BOIS-D'HAINE, PHARMACIE DE BASCOUP, PHARMACIE SENEFFE CENTRE, Pharmacie LOISEAU, PHARMACIE ANNE ANDRE, MARIEC.C-PHARMA, PHARMACIE DE LA GRAND RUE +2 more

since 2014

Shareholders

DEVANTHINIC PHARMA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Canadiens 24

7180 Seneffe

2.229.432.954

Avenue Max Buset(PAU) 3

7100 La Louvière

Active since 10 December 2007

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.

All companies at this address →

PHARMACIE DE LA DRÊVE same network

€ 287,815 gross margin · 2025

PHARMACIE DE BOIS-D'HAINE same network

€ 317,344 gross margin · 2025

PHARMACIE DE BASCOUP same network

€ 517,152 gross margin · 2025

PHARMACIE SENEFFE CENTRE same network

€ 576,922 gross margin · 2025

PHARMACIE ANNE ANDRE same network

€ 357,760 gross margin · 2025

+6 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0894.160.549
VAT number: BE 0894.160.549
Registered office: Rue des Canadiens 24, 7180 Seneffe
Names & denominations: PHARMA-LOUVE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 13 December 2007
Peppol: Active · Active since 29 Dec 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗